🏥 Prescribed at our clinic: Our endocrinologists prescribe and manage Mounjaro for patients in Houston, Sugar Land, and Memorial City. Book a consultation →
Mounjaro (tirzepatide) is a once-weekly injectable medication by Eli Lilly, FDA-approved for Type 2 diabetes management. It is in a class of its own — not a standard GLP-1, but a dual GIP/GLP-1 receptor agonist that activates both the GLP-1 and GIP hormone pathways simultaneously. This dual action produces some of the most powerful blood sugar reduction and weight loss results ever seen in a diabetes medication.
📌 Mounjaro vs. Zepbound: Same drug (tirzepatide), different brand names. Mounjaro is prescribed for Type 2 diabetes; Zepbound is prescribed for weight management. The distinction matters for insurance coverage.
What Makes Mounjaro Different: Dual GIP + GLP-1 Action
Most GLP-1 medications (Ozempic, Wegovy, Victoza, Trulicity) activate only the GLP-1 receptor. Mounjaro activates two receptors:
Stimulates insulin release, suppresses glucagon, slows gastric emptying, reduces appetite. Same pathway as Ozempic/Wegovy.
GIP is the other major incretin hormone. Activating it amplifies insulin response and appears to enhance fat metabolism and reduce fat storage in ways GLP-1 alone cannot.
The result: Mounjaro produces greater A1c reductions, greater weight loss, and comparable (likely superior) cardiovascular benefits compared to GLP-1-only agents.
Mounjaro Dosing
- Starting dose: 2.5 mg once weekly for 4 weeks
- Increase by: 2.5 mg every 4 weeks as tolerated
- Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
- Maximum dose: 15 mg once weekly
- Injected subcutaneously in the abdomen, thigh, or upper arm
Clinical Results
- A1c reduction: Up to 2.0–2.3% reduction from baseline — among the highest of any diabetes medication
- Weight loss (diabetes trials): 15–21% of body weight depending on dose — substantially more than semaglutide
- Head-to-head vs. Ozempic: SURPASS-CVOT trial showed tirzepatide reduced A1c more and caused more weight loss than semaglutide 1 mg
- Blood pressure: Meaningful reductions in systolic BP
- Cholesterol: Improvements in triglycerides and HDL
GLP-1 / GIP Medication Comparison
| Brand | Drug | Receptor | FDA Approval | Avg. Weight Loss |
|---|---|---|---|---|
| Ozempic | Semaglutide | GLP-1 | Type 2 Diabetes | ~5–7% |
| Wegovy | Semaglutide | GLP-1 | Weight Management | ~15% |
| Mounjaro | Tirzepatide | GIP + GLP-1 | Type 2 Diabetes | ~15–20% |
| Zepbound | Tirzepatide | GIP + GLP-1 | Weight Management | ~20–22% |
Frequently Asked Questions About Mounjaro
What is Mounjaro and how does it work?
Mounjaro (tirzepatide) is a once-weekly injectable medication by Eli Lilly, FDA-approved for Type 2 diabetes. Unlike GLP-1 receptor agonists such as Ozempic, Mounjaro activates TWO receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual action produces more powerful blood sugar lowering and more weight loss than GLP-1 alone. Mounjaro's diabetes approval came in 2022; tirzepatide for weight loss was approved under the brand name Zepbound in 2023.
How much weight do people lose on Mounjaro?
In diabetes trials (SURPASS program), patients on Mounjaro lost an average of 15–21% of body weight depending on the dose — significantly more than Ozempic at equivalent doses. In obesity-specific trials (SURMOUNT), tirzepatide (as Zepbound) produced average weight loss of 20–22%. These are the largest weight reductions ever seen in a medication trial for obesity.
What is the difference between Mounjaro and Ozempic?
The key difference is the mechanism: Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, while Ozempic (semaglutide) activates only GLP-1. In head-to-head trials (SURPASS-CVOT), tirzepatide produced greater A1c reduction and greater weight loss than semaglutide. Mounjaro is approved for Type 2 diabetes; Ozempic is also approved for Type 2 diabetes. For weight loss, Zepbound vs. Wegovy is the relevant comparison.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound contain exactly the same drug — tirzepatide — made by Eli Lilly. They differ only in FDA-approved indication and how they are billed to insurance: Mounjaro uses Type 2 diabetes coverage, while Zepbound uses obesity/weight management coverage. If you have Type 2 diabetes, your endocrinologist may prescribe Mounjaro. If your primary goal is weight loss without a diabetes diagnosis, Zepbound is the appropriate version to request for insurance purposes.
What are the side effects of Mounjaro?
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation — most prominent when starting or increasing the dose. These typically improve over several weeks. Rare but serious risks include pancreatitis and gallbladder disease. Like other GLP-1 class drugs, there is a theoretical thyroid tumor risk based on animal data. Your endocrinologist will review contraindications and monitor you appropriately.
Is Mounjaro covered by insurance?
Mounjaro has good coverage through commercial insurance for patients with a Type 2 diabetes diagnosis — similar to Ozempic. Prior authorization is commonly required. Without a diabetes diagnosis, patients often seek Zepbound, which uses obesity coverage pathways. Coverage varies by insurer and plan. Our team verifies benefits and assists with prior authorization.
Can an endocrinologist prescribe Mounjaro in Houston?
Yes. Our board-certified endocrinologists at Endocrine & Diabetes Plus Clinic of Houston prescribe and manage Mounjaro for patients with Type 2 diabetes throughout the Houston area, including Sugar Land and Memorial City. We evaluate your complete metabolic picture — A1c, weight, cardiovascular risk, kidney function — to determine the optimal medication and dose for you.
Key Takeaways
- Mounjaro (tirzepatide) is FDA-approved for Type 2 diabetes and activates both GLP-1 and GIP receptors
- Produces greater A1c reduction and weight loss than semaglutide (Ozempic) in head-to-head trials
- Average 15–21% weight loss in diabetes trials — highest of any diabetes medication to date
- Same drug as Zepbound — different name and insurance pathway for weight management use
- An endocrinologist ensures proper evaluation, dosing, and monitoring